One where access to quality health care is more equitably distributed among the world's women. Where the most accurate, reliable technology is also designed for affordability and ease of use. Where poor women no longer die of an easily treatable cancer because they can't afford screening and, when they do get screened, face barriers to appropriate follow-up care.
By developing an innovative embodiment of an established method for cervical cancer screening. Our test will deliver immediate screening results, provide a digital map of the cervix which can be shared via ehealth applications (mobile phone), linking screening to follow-up care or expert consultation in ways that have previously not been possible. The technology is affordable - less than $2 a test kit. By working from the very beginning with clinical partners who serve rural and low-income women, and in communities where healthcare workers and facilities are scarce, we have designed the product to be easy to use by community health workers with minimal training. The sytem will be field robust (reliable in variable settings, portable and with a solar powered version). Unlike the current standard of care, the Pap test (with/without adjunct HPV screening), there will be no need for lab services that are often difficult to access in low income settings.
We decided to start our own mission-driven business, with an emphasis on improving access to screening for low income women, after our Co-founder/CEO was involved in the development of a similar commercial product that was essentially derailed by the purely financial perspective of its investors. We have worked for years to get to the point where we are now, which is that we are ready to assemble a fully integrated prototype device. With this prototype, we will be able to begin gathering clinical data from our research partners, and with that data in hand we will be able to attract impact investors. Right now we are considered too risky and early stage by the investors we have approached. We are in the impossible cycle of needing preliminary clinical data to raise investment funds, and needing money to collect preliminary clinical data. We hope that individuals who are interested in supporting social ventures will step up to get us through this phase. As a business that could be extremely financially successful in high-income markets after an initial launch in low-income markets, we could be the social venture blockbuster that the field is looking for.